Clinical Trial Update: Japanese Study of the Combined Administration of Docetaxel With Prednisolone for Metastatic Hormone Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial in Japan evaluating the combination of docetaxel and prednisolone for metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Prednisolone (Prednisolone)

Snippet

Sponsor: Sanofi | Conditions: Therapy, Prostatic Neoplasms | Phase 2 | Status: COMPLETED